Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Aug 1;30(8):1430-1434.
doi: 10.1093/ibd/izad198.

Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease

Yoo Jin Lee  1   2 , Dalin Li  1 , Angela Mujukian  1 , Philip Debbas  1 , Melissa Hampton  1 , Emebet Mengesha  1 , Susan Cheng  3 , Joseph E Ebinger  3 , Michael Chiorean  4 , Donald Lum  5 , Oriana M Damas  6 , Jonathan Braun  1 , Dermot P B McGovern  1 , Gil Y Melmed  1 ; CORALE-IBD Study Group
Collaborators, Affiliations
Observational Study

Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease

Yoo Jin Lee et al. Inflamm Bowel Dis. .
No abstract available

Keywords: SARS-CoV-2; Vaccination; adverse event; inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

G.M.: Consultant for Abbvie, Arena Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim, Ferring, Genentech, Gilead, Janssen, Pfizer, Prometheus Labs, Samsung Bioepis, and Takeda.

D.M.: Consultant for Gilead, Takeda, Pfizer, Boehringer Ingelheim, Bridge Biotherapeutics, Prometheus Biosciences Inc, and Prometheus Labs. Stock options in Prometheus Biosciences Inc.

Figures

Figure 1.
Figure 1.
A, Severity of postvaccination symptoms after each mRNA SARS-CoV-2 vaccine dose in participants who received at least 1 vaccine dose. B, Severity of postvaccination symptoms after each mRNA SARS-CoV-2 vaccine dose in participants who completed all 4 doses of vaccination.
See this image and copyright information in PMC

References

    1. Loubet P, Launay O.. What a second booster dose of mRNA COVID-19 vaccines tells us. Lancet Infect Dis. 2022;22(8):1092-1093. - PMC - PubMed
    1. Munro APS, Feng S, Janani L, et al. ; COV-BOOST study group. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131-1141. - PMC - PubMed
    1. Li D, Debbas P, Mujukian A, et al. Postvaccination symptoms after a third dose of mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease: results from CORALE-IBD. Inflamm Bowel Dis. 2022;29(6):883-887. - PMC - PubMed
    1. Botwin GJ, Li D, Figueiredo J, et al. Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol. 2021;116(8):1746-1751. - PMC - PubMed
    1. Melmed GY, Botwin GJ, Sobhani K, et al. Antibody responses after SARS-CoV-2 mRNA vaccination in adults with inflammatory bowel disease. Ann Intern Med. 2021;174(12):1768-1770. - PMC - PubMed

Publication types